ATE406155T1 - Triptolid-prodrugs zur krebstherapie - Google Patents
Triptolid-prodrugs zur krebstherapieInfo
- Publication number
- ATE406155T1 ATE406155T1 AT02704187T AT02704187T ATE406155T1 AT E406155 T1 ATE406155 T1 AT E406155T1 AT 02704187 T AT02704187 T AT 02704187T AT 02704187 T AT02704187 T AT 02704187T AT E406155 T1 ATE406155 T1 AT E406155T1
- Authority
- AT
- Austria
- Prior art keywords
- cancer therapy
- triptolide prodrugs
- prodrugs
- triptolide
- irinotecan
- Prior art date
Links
- DFBIRQPKNDILPW-CIVMWXNOSA-N Triptolide Chemical compound O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)[C@@H](O)[C@]21[C@H]3O1 DFBIRQPKNDILPW-CIVMWXNOSA-N 0.000 title abstract 2
- 229940002612 prodrug Drugs 0.000 title abstract 2
- 239000000651 prodrug Substances 0.000 title abstract 2
- YKUJZZHGTWVWHA-UHFFFAOYSA-N triptolide Natural products COC12CC3OC3(C(C)C)C(O)C14OC4CC5C6=C(CCC25C)C(=O)OC6 YKUJZZHGTWVWHA-UHFFFAOYSA-N 0.000 title abstract 2
- 238000011275 oncology therapy Methods 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 229960002949 fluorouracil Drugs 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 229960004768 irinotecan Drugs 0.000 abstract 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/766,156 US6620843B2 (en) | 2001-01-19 | 2001-01-19 | Anticancer treatment using triptolide prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE406155T1 true ATE406155T1 (de) | 2008-09-15 |
Family
ID=25075572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02704187T ATE406155T1 (de) | 2001-01-19 | 2002-01-18 | Triptolid-prodrugs zur krebstherapie |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6620843B2 (enExample) |
| EP (1) | EP1359909B1 (enExample) |
| JP (1) | JP2004517882A (enExample) |
| AT (1) | ATE406155T1 (enExample) |
| AU (1) | AU2002237884B2 (enExample) |
| CA (1) | CA2435322A1 (enExample) |
| DE (1) | DE60228544D1 (enExample) |
| WO (1) | WO2002056835A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2485794C (en) | 2002-05-31 | 2012-10-16 | Pharmagenesis, Inc. | Triptolide derivatives for modulation of apoptosis and immunosuppression |
| CN100398544C (zh) * | 2002-09-18 | 2008-07-02 | 成都达远药物有限公司 | 高免疫抑制活性的水溶性雷公藤内酯醇衍生物及其应用 |
| EP1581208A1 (en) * | 2002-12-17 | 2005-10-05 | Pharmagenesis, Inc. | Triptolide derivatives as immunomodulator and anticancer agents |
| US6943259B2 (en) * | 2003-02-25 | 2005-09-13 | Pharmagenesis, Inc. | Halogenated triptolide derivatives as immunomodulators and anticancer agents |
| WO2005062913A2 (en) * | 2003-12-24 | 2005-07-14 | Pharmagenesis, Inc. | Triplide 5,6-derivatives as immunomodulators and anticancer agents |
| CN1917893A (zh) * | 2004-02-09 | 2007-02-21 | 美国泛华医药公司 | 从雷公藤多苷中分离雷公藤内酯醇化合物的方法 |
| JP5057966B2 (ja) * | 2004-03-02 | 2012-10-24 | ファーマジェネシス， インコーポレイテッド | 免疫調節剤および抗癌剤としてのトリプトライドラクトン環誘導体 |
| WO2006012204A2 (en) * | 2004-06-25 | 2006-02-02 | Pharmagenesis, Inc. | Method for treatment of inflammatory disorders using triptolide compounds |
| US8617906B2 (en) * | 2004-10-13 | 2013-12-31 | Pharmagenesis, Inc. | Identification and screening of triptolide target molecules |
| EP1946758A1 (en) * | 2007-01-18 | 2008-07-23 | Pierre Fabre Medicament | Treatment of acute myeloid leukemia |
| US20100087337A1 (en) | 2008-09-10 | 2010-04-08 | Bind Biosciences, Inc. | High Throughput Fabrication of Nanoparticles |
| WO2010091193A2 (en) | 2009-02-05 | 2010-08-12 | Pharmagenesis, Inc. | Triptolide c-ring derivatives as anticancer agents and immune modulators |
| US9150600B2 (en) | 2009-05-07 | 2015-10-06 | Regents Of The University Of Minnesota | Triptolide prodrugs |
| PT2427467E (pt) * | 2009-05-07 | 2015-11-19 | Univ Minnesota | Profármacos de triptólido |
| US20130195896A1 (en) * | 2010-04-07 | 2013-08-01 | Steward Research And Specialty Projects Corporation | Compositions and methods for the treatment of a neoplasia |
| US9846160B2 (en) | 2012-02-27 | 2017-12-19 | Board Of Regents, The University Of Texas Systems | Ganglioside GD2 as a marker and target on cancer stem cells |
| CA3013619A1 (en) * | 2016-02-04 | 2017-08-10 | The Johns Hopkins University | Glucose conjugates of triptolide, analogs and uses thereof |
| CN107698653B (zh) * | 2017-10-11 | 2019-08-27 | 中国农业科学院蜜蜂研究所 | 一种雷公藤甲素半抗原及其制备方法与应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4005108A (en) | 1973-04-03 | 1977-01-25 | Research Corporation | Novel anti-leukemic diterpenoid triepoxides |
| US5919816A (en) * | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| US5663335A (en) * | 1996-03-01 | 1997-09-02 | Pharmagenesis, Inc. | Immunosuppressive compounds and methods |
| US5962516A (en) | 1997-02-28 | 1999-10-05 | Pharmagenesis, Inc. | Immunosuppressive compounds and methods |
| JP2002523495A (ja) | 1998-09-02 | 2002-07-30 | ファーマジェネシス， インコーポレイテッド | 高い水溶性を有するトリプトリドプロドラッグ |
| US6548537B1 (en) * | 1998-09-02 | 2003-04-15 | Pharmagenesis, Inc. | Triptolide prodrugs having high aqueous solubility |
| US6294546B1 (en) * | 1999-08-30 | 2001-09-25 | The Broad Of Trustees Of The Leland Stanford Junior University | Uses of diterpenoid triepoxides as an anti-proliferative agent |
| WO2002074759A1 (en) * | 2001-03-15 | 2002-09-26 | Pharmagenesis, Inc. | Amino acid derivatives of triptolide compounds as immune modulators and anticancer agent |
-
2001
- 2001-01-19 US US09/766,156 patent/US6620843B2/en not_active Expired - Fee Related
-
2002
- 2002-01-18 AT AT02704187T patent/ATE406155T1/de not_active IP Right Cessation
- 2002-01-18 WO PCT/US2002/001650 patent/WO2002056835A2/en not_active Ceased
- 2002-01-18 EP EP02704187A patent/EP1359909B1/en not_active Expired - Lifetime
- 2002-01-18 JP JP2002557346A patent/JP2004517882A/ja active Pending
- 2002-01-18 CA CA002435322A patent/CA2435322A1/en not_active Abandoned
- 2002-01-18 DE DE60228544T patent/DE60228544D1/de not_active Expired - Fee Related
- 2002-01-18 AU AU2002237884A patent/AU2002237884B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004517882A (ja) | 2004-06-17 |
| DE60228544D1 (de) | 2008-10-09 |
| EP1359909B1 (en) | 2008-08-27 |
| CA2435322A1 (en) | 2002-07-25 |
| WO2002056835A2 (en) | 2002-07-25 |
| US6620843B2 (en) | 2003-09-16 |
| US20020099051A1 (en) | 2002-07-25 |
| WO2002056835A3 (en) | 2003-02-27 |
| EP1359909A4 (en) | 2005-03-09 |
| AU2002237884B2 (en) | 2006-08-17 |
| EP1359909A2 (en) | 2003-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60228544D1 (de) | Triptolid-prodrugs zur krebstherapie | |
| CY1112478T1 (el) | Ενωσεις κιναζολινονης ως αντικαρκινικοι παραγοντες | |
| SG160412A1 (en) | Anti-igfr1 antibody therapeutic combinations | |
| TW200612918A (en) | Lonidamine analogs | |
| PT1242060E (pt) | Tratamento da doenca metastatica | |
| MX2007012817A (es) | Eliminacion de poblacion celular heterogenea o mezclada en tumores. | |
| NZ597098A (en) | Use of pegylated il-10 to treat cancer | |
| WO2004103301A3 (en) | Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents | |
| DK1556058T3 (da) | Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi | |
| HUP0400231A3 (en) | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer | |
| IL146125A0 (en) | Novel quinones as disease therapies | |
| WO2002102306A8 (en) | Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy | |
| TNSN07294A1 (en) | Treatment of metastasized tumors | |
| MX2009010269A (es) | Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana. | |
| EP1635764A4 (en) | CONJUGATE FOR THE SPECIFIC TARGETING OF ANTICANCER AGENTS ON CANCER CELLS AND PRODUCTION OF THE CONJUGATE | |
| PL369148A1 (en) | Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment | |
| EP1503748A4 (en) | DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY | |
| MX2007004596A (es) | Nitrobenzoindoles y su uso en terapia del cancer. | |
| AR024907A1 (es) | Uso de inhibidores de la produccion y/o accion de la il-18 y composiciones farmaceuticas formuladas con dichos inhibidores para el tratamiento demetastasis de tumores. | |
| WO2005123908A3 (en) | Novel cancer cell lines and uses thereof | |
| MXPA05008902A (es) | Soluciones de drogas en mentol. | |
| PT1803456E (pt) | Composições farmacêuticas que compreendem l-733060 para utilização no tratamento de tumores cancerígenos | |
| TW200504051A (en) | Novel acridine derivatives and their use as medicaments | |
| WO2004026846A8 (en) | Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy | |
| AR023726A1 (es) | Terapia con gch para el tratamiento del cancer de mama |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |